A Phase 3 interventional study of Bridging Chemotherapy and Induction Cycles A1-A3 in Medulloblastoma, sponsored by Nationwide Children's Hospital. Not yet recruiting at 2 sites in United States. Open to participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Nationwide Children's Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 245 studies in Medulloblastoma with a site in United States — 26 open to participants now, 53 under way, 2 of them phase 3. Medulloblastoma · United States.
Among the 245 studies in Medulloblastoma with a site in United States, this one is the 32nd largest by planned enrollment of the 215 interventional ones that give a count, is the only one that started in 2027, is one of 11 in phase 3, reaches primary completion later than 48 of the 52 other live ones, and was the 239th registered.
317 studies on the registry are indexed under Medulloblastoma; 52 are open to participants now.
Browse Medulloblastoma studies →26 of the 245 studies in Medulloblastoma with a site in United States are open now. Recruiting first, the newest first:
Robbie Majzner · Sites in United States
Ages 2–21
Sabine Mueller, MD, PhD · Sites in United States
Ages 1–25
St. Jude Children's Research Hospital · Sites in United States
Ages 10–25
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 3–22
University of Florida · Sites in United States
Ages 4–39
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 32 (84%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.
This study: Up to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
245 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 137 · Phase 2 87 · Phase 3 11 · Phase 4 2
First in 1992; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 31 across 255 interventional studies indexed under Medulloblastoma.
Median enrollment 30 across the 215 interventional studies, 139 across the 15 observational. Of the 181 that completed or were terminated, 57 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 245 have an industry lead sponsor. The 10 most frequent:
Nationwide Children's Hospital is the lead sponsor of 233 studies on the registry; 41 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.
Nationwide Children's Hospital has 3 studies filed under Medulloblastoma — fewer than ten, so there is no comparison to draw.
11 of the studies in Medulloblastoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04337177Valent Technologies, LLCFlavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | 2026-12 |
| NCT04661384City of Hope Medical CenterBrain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | 2027-01-12 |
| NCT06701812H. Lee Moffitt Cancer Center and Research InstituteDigoxin Medulloblastoma Study | 2027-02 |
| NCT04541082Jazz PharmaceuticalsPhase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | 2027-03-31 |
| NCT04185038Seattle Children's HospitalStudy of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | 2027-05 |
Add all 11 to your calendar (.ics) → With an account.
Among the 245 studies in Medulloblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).
In this study, two highly effective irradiation-sparing treatment regimens are being compared in patients with low-risk early childhood MB:
Both treatment regimens use high-dose i.v. MTX, but only the HIT-SKK regimen also uses intraventricular administration of MTX directly into the CSF in addition to i.v. MTX. Given the long-term neurocognitive deficits of MTX have been described in childhood leukemia, and the pathogenesis of MTX-induced CNS-damage has been described, this has raised some concerns. Similarly, highly intensive, HDCT containing "Head Start" chemotherapy carries specific risks for the neurocognitive outcomes. Encouragingly, five years after HIT-SKK treatment including intraventricular MTX, young children with MB have a mean fluid intelligence score of 93.8 points. The full-scale IQ after "Head Start" chemotherapy is 95.4 and likewise within normal range. On the other hand, highly intensive, HDCT/AuHCR containing "Head Start" chemotherapy carries specific risks for the neurocognitive outcomes. However, neurocognitive outcomes after the HIT-SKK and "Head Start" chemotherapy regimens are difficult to compare from existing data, because of small sample sizes and inhomogeneous assessment tools used in prior studies. Therefore, a confirmatory study utilizing the same measures administered at the same time points is required to identify clinically relevant differences. In addition, survival, occurrence of second malignancies, neurological and endocrine deficits, hearing loss, and psychosocial comorbidities are also of high relevance in survivors of MB and may differ after both regimens. Since these also severely limit the survivors' potential for activity and participation in everyday life and affect their parents and siblings as well, this information will also be recorded.
Inclusion Criteria for screening:
Exclusion Criteria for overall study:
Inclusion Criteria for Bridging chemotherapy (carboplatin/etopiside) in interventional arms:
Exclusion Criteria for bridging chemotherapy:
Inclusion Criteria for randomization:
Exclusion criteria for randomization:
-Patients are excluded from the interventional study if any of the following criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm A consists of 3 to 5 Induction chemotherapy cycles and one high-dose chemotherapy cycle evaluated in the "Head Start" 4 study.
Drug: Bridging Chemotherapy · Drug: Induction Cycles A1-A3 · Drug: Induction Cycles A4-5 · Drug: Consolidation Cycle A6
Arm B consists of 3 to 5 cycles of chemotherapy evaluated in the HIT-SKK'92 (Rutkowski et al. 2005) and HIT-2000 (NCT00303810) clinical studies.
Drug: Bridging Chemotherapy · Drug: HIT-SKK Chemotherapy Cycles B1-3 · Drug: Modified HIT-SKK Cycle B4-5
One bridging chemotherapy cycle consists of five days of therapy using Carboplatin and etoposide
Cisplatin, vincristin, etoposide, cyclophosphamide, high-dose methotrexate
Cisplatin, etoposide, cyclophosphamide, high-dose methotrexate
Carboplatin, thiotepa, etoposide
Cyclophosphamide, vincristine, high-dose methotrexate, carboplatin, etoposide, i.ventri. methotrexate
Cyclophosphamide, vincristine, carboplatin, etoposide
Neurocognitive Outcomes using WPPSIIV
To compare neurocognitive outcomes 2.5 years after diagnosis between patients randomized to the interventional arms A ("Head Start" 4) and B (HIT-SKK). Full-Scale Intelligence Quotient (IQ) as measured by the Wechsler Preschool and Primary Scale of Intelligence (WPPSIIV) administered to those between the ages of 2 years and 6 months to 7 years and 7 months old at 2.5 years after diagnosis (+/- 6 months).
Time frame: 105 months
PFS
Progression-free survival (PFS) compared between randomized groups
Time frame: 152 months
rtPFS
Radiotherapy-free/progression-free survival (rtPFS) compared between randomized groups
Time frame: 152 months
OS
Overall survival (OS) compared between randomized groups
Time frame: 152 months
Second malignancies
Incidence of second malignancies compared between randomized groups
Time frame: 152 months
Number of patients with treatment-related adverse events as assessed by CTCAE v5.0
Acute toxicities compared between randomized groups
Time frame: 152 months
Incidence of therapy-related deaths
Incidence of therapy-related deaths compared between randomized groups
Time frame: 152 months
Assessment of IQ in patients randomized to Head Start or HIT-SKK
Wechsler Intelligence Scale for Children (WISC-V) Full Scale IQ at 5 years after diagnosis (+/- 12 months range allowed), with the Wechsler Preschool and Primary Scale of Intelligence (WPPSI) Full Scale IQ Score used only for children \< 6 years old.
Time frame: 152 months
Assessment of Development and Adaptive Functioning using ABAS v2 or v3
Adaptive Behavior Assessment System (ABAS, versions II or 3) at diagnosis, 2.5- and 5 years after diagnosis will be used to compare patients randomized to Head Start or HIT-SKK.
Time frame: 152 months
Quality of Life Assessment using PedsQL Infant or PedsQL 4.0 parent-reported Quality of Life Measure
PedsQL Infant or PedsQL 4.0 parent-report QoL measure depending upon current age at the treatment timepoints. Questionnaires are quantified on a scale of 0-100 where higher scores indicate better outcomes/quality of life.
Time frame: 152 months
Correlation between neurocognitive outcomes and QoL
Correlation of neurocognitive outcomes (measured using WISC-V Full Scale IQ at 5 years after diagnosis) and quality of life (measured using PedsQL Infant) 5 years after diagnosis will be achieved using a regression for linear mixed model.
Time frame: 152 months
Assessment of impact on hearing using SIOP Boston scale
Ototoxicity will be assessed through hearing evaluation according to SIOP Boston scale (patients with normal Distortion-Product Otoacoustic Emissions (DPOAE) will be considered as not having hearing loss).
Time frame: 152 months
Number of patients with Leukoencephalopathy
LEP will be assessed 2.5 and 5 years after diagnosis compared between randomized groups using the modified Fazekas scale.
Time frame: 152 months
Compare PFS
To compare PFS between randomized groups in patients in CR at end of study therapy
Time frame: 152 months
Compare PFS
To compare PFS between subtypes of SHH-MB as defined by classification based on the Heidelberg brain tumor classifier Version 11 (or higher)
Time frame: 152 months
Assess rate of patients with cancer predisposition syndromes
To assess the rate of patients with genetically confirmed basal cell nevus syndrome (BCNS, Gorlin-Syndrome, OMIM: 109400), ELP1 and GPR161 cancer predisposition syndromes among eligible enrolled patients
Time frame: 152 months
Compare rtPFS
To compare rtPFS between subtypes of SHH-MB as defined by classification based on the Heidelberg brain tumor classifier Version 11 (or higher)
Time frame: 152 months
Compare OS
To compare OS between subtypes of SHH-MB as defined by classification based on the Heidelberg brain tumor classifier Version 11 (or higher)
Time frame: 152 months
Compare rtPFS
To compare rtPFS between randomized groups in patients in CR at end of study therapy
Time frame: 152 months
Compare OS
To compare OS between randomized groups in patients in CR at end of study therapy
Time frame: 152 months
Assessment of impact on hearing using Chang scales
Ototoxicity will be assessed through hearing evaluation according to Chang Scale (patients with normal Distortion-Product Otoacoustic Emissions (DPOAE) will be considered as not having hearing loss).
Time frame: 152 months
Association between neurocognitive and behavioral outcomes
Association of neurocognitive (measured using WISC-V Full Scale IQ at 5 years after diagnosis and WPPSI Full Scale IQ Score used only for children \< 6 years old) outcomes and behavioral outcomes (measured using ABAS v2 or v3) 5 years after diagnosis compared between randomized groups
Time frame: 152 months
Plan to share: Yes — This study is considered for publication in the scientific literature in a peer re-viewed journal, irrespective of the results. Study results may also be presented at one or more medical congresses and may be used for scientific exchange and teaching purposes. Additionally, this study and its results may be submitted for inclusion in all appropriate health authority study registries, as well as publication on health authority study registry websites, as required by local health authority regulations.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Oct 2034, 93 months later.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jan 2027, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nationwide Children's Hospital →